Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Why This Cheap Gaming-Focused Stock Is A Strong Buy Right Now

Published 02/14/2020, 01:51 AM
Updated 07/09/2023, 06:31 AM

Everi Holdings Inc. (NYSE:EVRI) provides technology for the casino industry, from gaming machines to fintech. EVRI shares have soared 80% in the last year but they are still cheap. Plus, Everi’s outlook appears strong heading into its fourth quarter 2019 earnings release and beyond.

The Everi Basics

Everi is a Las Vegas-based casino tech firm that offers a variety of gaming machines, services, and more. The company also sells financial services-focused products, player loyalty offerings, as well as intelligence and regulatory compliance solutions.

EVRI topped our Q3 earnings and revenue estimates back in November, with its Games and FinTech units helping drive its 12% top-line growth. Meanwhile, its quarterly earnings jumped from $0.03 in the year-ago period to $0.12 a share. And last quarter marked Everi’s 13th consecutive quarter of year-over-year revenue and Adjusted EBITDA expansion.

Investors should also note that the firm announced in mid-January that it extended its relationship with the New York Lottery for 10 more years. EVRI’s central system currently monitors and administers more than 17,000 Video Lottery Terminals across nine facilities in the state.

Other Fundamentals

Last quarter, Everi generated free cash flow of $11 million to push its total up to $39.3 million on the year. This strong cash generation has helped the company reduce its debt load.

The nearby chart, meanwhile, shows us just how impressive of a run EVRI stock has been on since the summer of 2016. EVRI stock was trading at roughly $1 per share in June 2016 and it currently hovers at around $13.60 per share.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Despite this run, Everi holds an “A” grade for Value in our Style Scores system, alongside an “A” for Growth. We can also see that its longer-term earnings revisions have trended heavily upward, especially for fiscal 2020 and 2021.

Outlook

Looking ahead, our current Zacks estimates call for Everi’s fourth quarter revenue to jump 11.6% to $133.3 million that would see it roughly match Q3’s growth. Meanwhile, its fiscal 2019 revenue is projected to pop over 11% to $521.4 million. The company’s 2020 sales are then expected to climb another 9.2% higher to $569.1 million.

At the bottom end of the income statement, Everi’s adjusted Q4 earnings are expected to skyrocket from a loss of -$0.04 per share in the year-ago period to +$0.08.

Overall, its fiscal 2019 EPS figure is projected to soar 250% from $0.10 to $0.35 a share. And in a sign of continued expansion, EVRI’s 2020 earnings are expected to reach $0.58, which would mark another 65% climb.

Bottom Line

Everi’s solid earnings estimate revisions activity helps it earn a Zacks Rank #1 (Strong Buy) at the moment. The stock also rocks an overall “A” VGM grade, with it set to report its Q4 results on March 2. And some investors might be attracted to its “cheap” price of well under $20 a share.

In the end, Everi appears to be a stock worth considering given its growth outlook, within a gaming-focused space that includes other highly-ranked stocks such as MGM Resorts International (NYSE:MGM) , Churchill Downs (NASDAQ:CHDN) , and fellow low-priced SciPlay Corporation (NASDAQ:SCPL) . And let’s not forget that U.S. unemployment remains low and indexes rest right near their new highs despite coronavirus fears.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



MGM Resorts International (MGM): Free Stock Analysis Report

Churchill Downs, Incorporated (CHDN): Free Stock Analysis Report

Everi Holdings Inc. (EVRI): Free Stock Analysis Report

SciPlay Corporation (SCPL): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.